Saturday, June 15, 2024

New Hope for Multiple Myeloma Patients: Nexpovio with Dexamethasone Receives Official Recommendation

Similar articles

In a significant development for the treatment of multiple myeloma, selinexor (marketed as Nexpovio) combined with dexamethasone has been officially recommended for adults with relapsed or refractory multiple myeloma who have undergone four or more prior therapies. This recommendation was detailed in a recent report highlighting that this treatment combination is specified for patients with penta-refractory multiple myeloma — a condition unresponsive to multiple standard treatments including two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

The decision, supported by the National Institute for Health and Care Excellence (NICE), is based on the clinical need for more effective treatment options in the fifth or subsequent lines of therapy, where other treatments have failed. Despite the absence of direct clinical trial comparisons with best supportive care (BSC), indirect evidence suggests that selinexor plus dexamethasone can extend patient survival more effectively than BSC alone.

Multiple Myeloma

Nexpovio Approved for Advanced Multiple Myeloma: A Cost-Effective Lifeline

Nexpovio, developed by Menarini Stemline, is an oral medication that, when combined with dexamethasone, offers a new mechanism of action for treating this complex and severe cancer, which has seen few advances in treatment options at such advanced stages. The treatment’s list price stands at £3,680 per week for the standard dosage, but it is offered to the NHS at a confidential discounted rate, enhancing its cost-effectiveness and accessibility.

The committee’s endorsement stems from a comprehensive evaluation of the drug’s impact on quality of life and survival, weighed against its cost. The economic analysis, factoring in the severity of penta-refractory multiple myeloma and its life-limiting prognosis, supports the drug’s use below the cost-effectiveness thresholds set by NICE.

This recommendation marks a crucial step forward in the management of multiple myeloma, providing a lifeline to patients who have exhausted other options. The healthcare system is required to integrate this treatment into practice promptly, ensuring that eligible patients can access this potentially life-extending therapy without undue delay.

 

Resource: National Institute for Health and Care Excellence, May 08, 2024

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article